Previous 10 | Next 10 |
As a pre-revenue biotech company that's approaching decisive clinical and regulatory milestones, Anavex Life Sciences (NASDAQ: AVXL) isn't an investment for the faint of heart. It has no products on the market, and its share price is, for now, entirely dependent on how much the results of...
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
Summary On December 1, 2022 Anavex presented data from its Phase II/III Alzheimer's study claiming it met its primary and secondary endpoints. The way the endpoints were discussed led to confusion regarding which were the primary endpoints. Of the endpoints presented, there are nume...
Summary Anavex's 2-73/blarcamesine produced significant reductions in cognitive decline in early Alzheimer's disease as measured by ADAS-Cog and CDR-SB scores. Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically s...
Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2. Unfortunately,...
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
Shares of Anavex Life Sciences (NASDAQ: AVXL) were surging 44.9% higher as of 11:09 a.m. ET on Friday. The huge jump came after the company reported the results Thursday evening from a phase 2b/3 clinical study evaluating Anavex 2-73 (blarcamesine) in treating early Alzheimer's disease. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: pathdoc / Shutterstock.com Anavex Life Sciences (NASDAQ: AVXL ) stock is rocketing higher on Friday following positive results from a clinical trial . The results come from its Phase 2b/3 clinical trial o...
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results Plan to Meet with Regulatory Authorities to Determi...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
LOS ANGELES, April 16, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceu...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...